Search
FibroGen Inc
FGENAdd to Watchlist
9.710USD
0.0000.00%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
30.56MMarket Cap
0.18P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-01-07The current earnings forecast score of FibroGen Inc is 7.00, ranking 316 out of 398 in the Biotechnology & Medical Research industry. The average price target is 43.00, with a high of 43.00 and a low of 43.00.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
43.000
Target Price
+469.54%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
FibroGen Inc
FGEN
2
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is FibroGen Inc's expected revenue for the next quarter?
FibroGen Inc's expected revenue is 1.22M.
What is FibroGen Inc's price target?
Analysts forecast that FibroGen Inc's price target is USD 43.00, with the highest forecast at USD 43.00 and the lowest forecast at USD 43.00.
How have FibroGen IncFGEN's recent earnings per share performed?
The market expectation was USD -3.76, while FibroGen IncFGEN's earnings per share (EPS) for the previous quarter was USD 45.38. EPS for the next quarter is expected at USD -3.27.
What is the analyst rating for FibroGen Inc?
Based on the ratings of FibroGen Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.